Novartis Q4 Results
↓
↑
Content
Click below to navigate
through the document
TNO155 - SHP2 inhibitor
Company overview
Financial review
Conclusions
NCT03114319 (CTNO155X2101)
Solid tumors (single agent)
Phase 1
Indication
Phase
Patients
255
Number of participants with adverse events
Number of participants with dose limiting toxicities
Drug: TNO155
Drug: TNO155 in combination with EGF816 (nazartinib)
Adult patients with advanced solid tumors in selected indications
Appendix
Innovation: Pipeline overview
Financial performance
Innovation: Clinical trials
Cardiovascular, Renal
and Metabolic
Immunology
Neuroscience
> Oncology
Other
Global Health
Abbreviations
Primary
Outcome
Measures
Arms
Intervention
Target Patients
Readout
Milestone(s)
Publication
2025
TBD
References
□ NOVARTIS Reimagining Medicine
Novartis Q4 Results | January 31, 2024
77View entire presentation